BEGAIN | Brain-enriched guanylate kinase-associated | | | | | | Tissue enhanced |
BEST3 | Bestrophin 3 | Predicted membrane proteins
| | | | | Tissue enhanced |
BEX1 | Brain expressed, X-linked 1 | | | | | | Tissue enhanced |
BEX2 | Brain expressed X-linked 2 | | | | | | Tissue enhanced |
BEX5 | Brain expressed, X-linked 5 | | | | | | Tissue enhanced |
BHLHE22 | Basic helix-loop-helix family, member e22 | Transcription factors
| | | | | Tissue enhanced |
BRINP3 | Bone morphogenetic protein/retinoic acid inducible neural-specific 3 | Predicted secreted proteins
| | | | | Tissue enhanced |
BRSK2 | BR serine/threonine kinase 2 | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
C12orf68 | Chromosome 12 open reading frame 68 | | | | | | Tissue enhanced |
C14orf132 | Chromosome 14 open reading frame 132 | Predicted membrane proteins
| | | | | Tissue enhanced |
C15orf59 | Chromosome 15 open reading frame 59 | | | | | | Tissue enhanced |
C17orf96 | Chromosome 17 open reading frame 96 | | | | | | Tissue enhanced |
C19orf26 | Chromosome 19 open reading frame 26 | Predicted membrane proteins
| | | | | Tissue enhanced |
C1orf64 | Chromosome 1 open reading frame 64 | | | | | | Tissue enhanced |
C1orf95 | Chromosome 1 open reading frame 95 | Predicted membrane proteins
| | | | | Tissue enhanced |
C21orf37 | Chromosome 21 open reading frame 37 | | | | | | Tissue enhanced |
C22orf24 | Chromosome 22 open reading frame 24 | | | | | | Tissue enhanced |
C2orf82 | Chromosome 2 open reading frame 82 | Predicted membrane proteins
| | | | | Tissue enhanced |
C3orf80 | Chromosome 3 open reading frame 80 | Predicted membrane proteins
| | | | | Tissue enhanced |
C5orf64 | Chromosome 5 open reading frame 64 | | | | | | Tissue enhanced |
C8orf56 | Chromosome 8 open reading frame 56 | | | | | | Tissue enhanced |
C9orf172 | Chromosome 9 open reading frame 172 | | | | | | Tissue enhanced |
CA10 | Carbonic anhydrase X | Predicted secreted proteins
| | | | | Tissue enhanced |
CA11 | Carbonic anhydrase XI | Predicted secreted proteins
| | | | | Tissue enhanced |
CABP7 | Calcium binding protein 7 | Predicted membrane proteins
| | | | | Tissue enhanced |
CACNA1A | Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA1G | Calcium channel, voltage-dependent, T type, alpha 1G subunit | FDA approved drug targets Plasma proteins Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA1I | Calcium channel, voltage-dependent, T type, alpha 1I subunit | FDA approved drug targets Plasma proteins Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNB4 | Calcium channel, voltage-dependent, beta 4 subunit | Disease related genes FDA approved drug targets Plasma proteins Transporters
| | | | | Tissue enhanced |
CADM4 | Cell adhesion molecule 4 | Predicted membrane proteins
| | | | | Tissue enhanced |
CADPS | Ca++-dependent secretion activator | Plasma proteins
| | | | | Tissue enhanced |
CALN1 | Calneuron 1 | Predicted membrane proteins
| | | | | Tissue enhanced |
CAMK1G | Calcium/calmodulin-dependent protein kinase IG | Enzymes Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CAMK2N1 | Calcium/calmodulin-dependent protein kinase II inhibitor 1 | | | | | | Tissue enhanced |
CAMKK1 | Calcium/calmodulin-dependent protein kinase kinase 1, alpha | Enzymes
| | | | | Tissue enhanced |
CBLN4 | Cerebellin 4 precursor | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CCDC177 | Coiled-coil domain containing 177 | | | | | | Tissue enhanced |
CCDC85A | Coiled-coil domain containing 85A | Predicted secreted proteins
| | | | | Tissue enhanced |
CCK | Cholecystokinin | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CCSAP | Centriole, cilia and spindle-associated protein | | | | | | Tissue enhanced |
CDH22 | Cadherin 22, type 2 | Predicted membrane proteins
| | | | | Tissue enhanced |
CDH4 | Cadherin 4, type 1, R-cadherin (retinal) | Predicted membrane proteins
| | | | | Tissue enhanced |
CDH7 | Cadherin 7, type 2 | Predicted membrane proteins
| | | | | Tissue enhanced |
CDK5R1 | Cyclin-dependent kinase 5, regulatory subunit 1 (p35) | | | | | | Tissue enhanced |
CDKL5 | Cyclin-dependent kinase-like 5 | Disease related genes Enzymes Plasma proteins Potential drug targets
| | | | | Tissue enhanced |
CELSR3 | Cadherin, EGF LAG seven-pass G-type receptor 3 | G-protein coupled receptors Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CGREF1 | Cell growth regulator with EF-hand domain 1 | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CHADL | Chondroadherin-like | Predicted secreted proteins
| | | | | Tissue enhanced |
CHL1 | Cell adhesion molecule L1-like | Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CHRNA4 | Cholinergic receptor, nicotinic, alpha 4 (neuronal) | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |